查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1250773

到 2028 年的肝素市场预测——按来源、给药途径、剂型、成分、治疗方法、产品、应用、分销渠道、最终用户和地区进行的全球分析

Heparin Market Forecasts to 2028 - Global Analysis By Source, Global Heparin Market, By Administration Route, Dosage Form, Ingredient, Therapeutics, Product, Application, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 175+ Pages | 商品交期: 2-3个工作天内

价格

据 Stratistics MRC 预计，2022 年全球肝素市场规模将达到 74 亿美元，预计到 2028 年将达到 86 亿美元，预测期内復合年增长率为 2.4%实现

肝素被认为是维持生命最重要的药物之一。 肝素是一种抗凝剂。 肝素用于治疗多种慢性疾病。 这种药物具有很强的抗炎作用。 静脉注射或皮下注射。 管理心臟、骨科、深静脉血栓形成、肺栓塞和肾臟疾病。 它还用于管理主要的骨科手术，例如髋关节和膝关节置换术。 它可以防止患有某些疾病和接受心臟直视手术、旁路手术、肾透析和输血等医疗程序的患者血液凝固。

根据 CDC 的数据，2022 年美国每年有 659,000 人死于心脏病，即每 4 人中就有 1 人死于心脏病，是美国的主要死因之一。它已经完成了。

市场动态：

驱动程序

慢性病和手术的患病率增加

接受骨科手术、深静脉血栓形成、肺栓塞、肾臟疾病和心臟手术的患者数量增加，在这些手术中使用肝素导致肝素用量增加。 它的作用是减少血液凝固，防止手术过程中过度凝固，并且有一些标籤外用途。 肝素主要对某些患者有帮助，尤其是那些必须接受某些类型的手术或必须长时间卧床的患者。 这些因素正在推动市场需求。

约束

有害的副作用

误用或不当使用肝素可能会导致关节疼痛、僵硬、腰痛、出血、吐血、伤口出血和腹痛。 负面影响需要时间来治愈。 它也很刺激，会引起强烈的不适。 这些副作用常常使治疗变得困难并增加治疗费用。 这些因素阻碍了市场的增长。

机会

加强政府支持

国家投入资金研发肝素，疗效更高、副作用更小的肝素诞生了。 肝素在减轻疼痛、促进早期康復、减少并发症和缩短住院时间方面非常有效。 因此，政府将缺乏家庭支持与政府资助医院的免费治疗结合起来。 这些方面正在推动市场扩张。

威胁

高昂的医疗费用和严格的规定

肝素治疗的价格相对较高。 需要每月定期随访。 频繁的治疗使其成为最昂贵的药物。 政府实施严格控制，因为高剂量会导致许多副作用。 使用频率高，副作用多，阻碍了市场拓展。

COVID-19 的影响

COVID-19 疫情大大增加了市场需求。 COVID患者常因促血栓自身抗体产生异常血栓，导致肺栓塞和深静脉血栓形成，为肝素提供了可乘之机。 低分子肝素早期抗凝治疗可有效预防 COVID 相关的凝血功能障碍和内皮损伤，改善患者预后。 这些因素在大流行期间增加了市场需求。

门诊部分预计在预测期内最大

门诊部分由于其高度便利和服务，预计将有良好的增长。 减少医院开支，包括与住院和其他招待有关的开支，使门诊病人比其他病人更有优势。 这个市场的很大一部分主要归功于低价格、扩大的服务范围和患者的舒适度。

在预测期内，预计静脉注射业务的复合年增长率最高

由于其可用性，预计静脉注射部分在预测期内将以最快的复合年增长率增长。 静脉内给药是用于给药肝素，尤其是普通肝素的方法。 它快速进入血液并迅速起作用以避免血栓。 静脉内给药还可以更轻鬆地控制血液中的药物浓度。

市场份额最高的地区

由于心血管疾病和事故的增加，预计在预测期内北美将占据最大的市场份额。 导致该地区高比例的其他变量包括医疗保健支出的增加和患者对该领域意识的提高。 该地区每年的死亡人数很高，即每 4 人中就有 1 人死亡。 这些因素正在推动该地区对肝素的需求。

复合年增长率最高的地区：

由于老年人口的增加，预计亚太地区在预测期内的复合年增长率最高。 亚太地区也是原料药和肝素麤品的最大供应商。 这有利于区域性公司，例如 Pharmax Lifesciences。 专利过期药品的仿製药在当地廉价生产。 高慢性病人口和不断扩大的经济是该地区市场增长的两个主要驱动力。

主要发展

2022 年 4 月，Novartis宣布引入新的组织结构和运营模式，旨在支持其作为一家专注于未来十年的製药公司的创新、增长和生产力雄心。.

2022年4月，Dr. Reddy's Laboratories Ltd.（以下简称“Dr. Reddy's”及其子公司、MediCane Health Inc.及其子公司宣布在德国推出医用大麻产品）宣布：作为一部分根据 Dr.Reddy's 与 MediCane 于 2021 年开始的合作，MediCane 将提供来自葡萄牙 EU-GMP 认证设施的医用大麻产品，以及后勤和监管支持。/p>

2021 年 3 月，Teva 宣布推出第一个仿製药 AZOPT(R)（布林佐胺滴眼液）1%。 它用于治疗由于高眼压症和开角型青光眼引起的眼部高血压。 它通过减少眼球中的液体起作用。 该产品由 Indoco Remedies 开发，将在其位于印度果阿的工厂生产。

我们的报告提供了什么

  • 区域和国家/地区细分市场份额评估
  • 向新进入者提出战略建议
  • 2020、2021、2022、2025 和 2028 年的综合市场数据
  • 市场驱动因素（市场趋势、制约因素、机遇、威胁、挑战、投资机会、建议等）
  • 根据市场预测在关键业务领域提出战略建议
  • 竞争格局和趋势
  • 公司简介，包括详细的战略、财务状况和近期发展
  • 供应链趋势反映了最新的技术进步。

提供免费定制

购买此报告的客户将免费获得以下定制之一。

  • 公司简介
    • 其他市场公司的综合概况（最多 3 家公司）
    • 主要公司的 SWOT 分析（最多 3 家公司）
  • 区域细分
    • 应客户要求提供主要国家/地区的市场估算、预测和復合年增长率（注意：基于可行性检查）
  • 竞争基准
    • 根据产品组合、地域分布和战略联盟对主要参与者进行基准测试

内容

第 1 章执行摘要

第二章前言

  • 概览
  • 利益相关者
  • 调查范围
  • 调查方法
    • 数据挖掘
    • 数据分析
    • 数据验证
    • 研究方法
  • 调查来源
    • 主要研究信息来源
    • 二手研究资源
    • 假设

第三章市场趋势分析

  • 司机
  • 约束因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第 4 章波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第 5 章全球肝素市场：按来源分类

  • 奶牛
  • 猪
  • 其他来源

第 6 章全球肝素市场：按给药途径

  • 皮下
  • 静脉注射
  • 其他给药途径

第 7 章全球肝素市场：按配方分类

  • 解决
  • 注入
  • 其他剂型

第 8 章全球肝素市场：按成分分类

  • 钠
  • 钙
  • 其他材料

第 9 章全球肝素市场：按疗法分类

  • 呼吸科
  • 心血管
  • 肾臟科
  • 肿瘤学
  • 中枢神经系统
  • 其他治疗

第 10 章全球肝素市场：按产品分类

  • 普通肝素
  • 低分子肝素
  • 超低分子量肝素
  • 其他产品

第 11 章全球肝素市场：按应用

  • 深静脉血栓形成
  • 冠状动脉疾病
  • 肺栓塞
  • 房颤
  • 静脉血栓栓塞症
  • 肾功能损害
  • 心脏病发作
  • 其他应用

第 12 章全球肝素市场：按分销渠道

  • 医院
  • 药店
  • 在线药店
  • 零售药房

第 13 章全球肝素市场：按最终用户分类

  • 住院病人
  • 门诊
  • 家庭护理
  • 其他最终用户

第 14 章全球肝素市场：按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 意大利
    • 法国
    • 西班牙
    • 其他欧洲
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 新西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中东和非洲
    • 沙特阿拉伯
    • 阿拉伯联合酋长国
    • 卡塔尔
    • 南非
    • 其他中东地区

第15章主要发展

  • 合同、伙伴关係、协作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十六章公司简介

  • LEO Pharma A/S
  • Dr. Reddy's Laboratories Ltd
  • Aspen Holdings
  • Novartis AG
  • GlaxoSmithKline plc
  • Teva Pharmaceuticals
  • Fresenius SE & Co
  • Sanofi
  • Viatris Inc
  • Baxter International Inc
  • Pfizer Inc
  • United Biotech Ltd
  • Syntex SA
  • B. Braun Medical Inc
  • Leap Labchem Co
  • Bristol-Myers Squibb Co
  • Anselm Pharmaceuticals
Product Code: SMRC22650

According to Stratistics MRC, the Global Heparin Market is accounted for $7.4 billion in 2022 and is expected to reach $8.6 billion by 2028 growing at a CAGR of 2.4% during the forecast period. Heparin is considered as one of the most essential drug for preserving life. It is a member of the anticoagulant medication family. Heparin is used as therapy for several chronic diseases. The drug possesses potent anti-inflammatory properties. It is injected into a vein or injected under the skin. It manages cardiac, orthopedic, deep vein thrombosis, pulmonary embolism, and renal disorders. Its use also extends to the administration of major orthopedic procedures such as hip and knee replacements. It prevents blood clotting in patients with specific medical conditions or who are undergoing medical procedures such as open-heart surgery, bypass surgery, kidney dialysis, and blood transfusions.

According to CDC in 2022, 659,000 people in the United States die from heart disease each year which is 1 in every 4 deaths and was marked as one of the major causes of death in the country.

Market Dynamics:

Driver:

Growing prevalence of chronic diseases and surgeries

The increasing number of patients having orthopedic, deep vein thrombosis, pulmonary embolism, renal diseases and cardiac operations, as well as the use of heparin in these surgeries raised the usage of heparin. It helps to keep the blood from clotting and prevents excessive coagulation during operations and supports several off-label uses. Heparin mostly helps certain patients, especially those who must have certain types of surgery or who must remain in bed for a long time. These factors are fuelling the market demand.

Restraint:

Adverse side-effects

Heparin misuse or improper dosage can result in joint pain, stiffness, backaches, bleeding, spitting up blood, oozing from wounds and abdominal pain. Negative effects take a while to recover from. They irritate and cause severe discomfort. These side effects frequently make treatment more difficult and raise the total cost of therapy. These factors are hindering the growth of the market.

Opportunity:

Rising government support

Government funds have been raised for heparin research and development that will create it with better therapeutic potential and fewer side effects. Heparin greatly enhances pain relief, promotes quicker recovery, reduces complications, and shortens hospital stays. So, the government combined the lack of familial support with the provision of free care at a government-funded hospital. These aspects are propelling the market expansion.

Threat:

High medical costs & stringent regulations

The price of heparin therapy is relatively high. It requires regular monthly follow ups. Frequent treatments are making it the most costly medication. Government imposed rigorous controls since the heavy dosage of drug causes numerous negative side effects. The market's expansion is being hampered by its increasingly frequent use and negative consequences.

Covid-19 Impact

The COVID-19 epidemic has greatly increased market demand. COVID patients frequently develop aberrant blood clots because of clot-promoting auto antibodies that cause pulmonary embolisms and deep vein thrombosis, which presents a heparin opportunity. Early anticoagulation treatment with low-molecular-weight heparin effectively prevents COVID associated coagulopathy and endotheliopathy, which improve patient prognosis. These factors raised the demand for the market during pandemic.

The outpatient segment is expected to be the largest during the forecast period

The outpatient segment is estimated to have a lucrative growth, due to its high convenience and services. Due to the decrease in hospital expenditures, including those associated with hospital admission and other forms of hospitality, outpatients have an advantage over other patients. The significant proportion of this market is mostly due to low prices, expanded service availability, and patient comfort.

The intravenous segment is expected to have the highest CAGR during the forecast period

The intravenous segment is anticipated to witness the fastest CAGR growth during the forecast period, due to its easy accessibility. The intravenous method is used to give heparin, particularly unfractionated heparin. It allows quick bloodstream entrance and works quickly to avoid blood clots. The intravenous form of administration also makes it simpler to manage drug concentration in the blood.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to the increase in cardiovascular diseases and accidents. Other variables that contribute to the region's high proportion include rising healthcare spending and rising patient awareness in this area. This region faces high annual deaths i.e. every 1 in 4 fatalities. These elements are raising the demand for heparin in this region.

Region with highest CAGR:

Asia Pacific is projected to have the highest CAGR over the forecast period, owing to the rising geriatric population. Moreover, Asia Pacific is the region that supplies the most API and crude heparin. This benefits regional businesses like Pharmax Lifesciences. Generic versions of medications whose patents have expired are produced locally at a reasonable price. Large chronically ill population and expanding economy are two of the main drivers of the market growth in this region.

Key Players in the market

Some of the key players profiled in the Heparin Market include LEO Pharma A/S, Dr. Reddy's Laboratories Ltd, Aspen Holdings, Novartis AG, GlaxoSmithKline plc, Teva Pharmaceuticals, Fresenius SE & Co, Sanofi, Viatris Inc, Baxter International Inc, Pfizer Inc, United Biotech Ltd, Syntex SA, B. Braun Medical Inc, Leap Labchem Co, Bristol-Myers Squibb Co and Anselm Pharmaceuticals.

Key Developments:

In April 2022, Novartis announced the introduction of a new organizational structure and operating model designed to support the company's innovation, growth, and productivity ambitions as a focused medicines company in the coming decade.

In April 2022, Dr.Reddy's Laboratories Ltd. Along with its subsidiaries together and MediCane Health Inc. with its subsidiaries together announced the launch of its medical cannabis product in Germany. As part of collaboration between Dr. Reddy's and MediCane that started in 2021, MediCane will supply the medical cannabis products to Dr. Reddy's from its EU-GMP-certified facilities in Portugal along with providing logistical and regulatory support.

In March 2021, Teva announced the launch of the first generic version of AZOPT® (brinzolamide ophthalmic suspension) 1%. This is used to treat high pressure inside the eye due to ocular hypertension and open-angle glaucoma. This works by decreasing the amount of fluid in the eye. The product was developed by Indoco Remedies and will be manufactured at its facility in Goa, India.

Sources Covered:

  • Bovine
  • Porcine
  • Other Sources

Administration Routes Covered:

  • Subcutaneous
  • Intravenous
  • Other Administration Routes

Dosage Forms Covered:

  • Solution
  • Injection
  • Other Dosage Forms

Ingredients Covered:

  • Sodium
  • Calcium
  • Other Ingredients

Therapeutics Covered:

  • Respiratory
  • Cardiovascular
  • Nephrology
  • Oncology
  • Central Nervous System
  • Other Therapeutics

Products Covered:

  • Unfractionated Heparin
  • Low Molecular Weight Heparin
  • Ultra-low Molecular Weight Heparin
  • Other Products

Applications Covered:

  • Deep Vein Thrombosis
  • Coronery Artery Disease
  • Pulmonary Embolism
  • Atrial Fibrillation
  • Venous Thromboembolism
  • Renal Impairment
  • Heart Attack
  • Other Applications

Distribution Channels Covered:

  • Hospitals
  • Drug Stores
  • Online Pharmacies
  • Retail Pharmacies

End Users Covered:

  • Inpatient
  • Outpatient
  • Homecare
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Heparin Market, By Source

  • 5.1 Introduction
  • 5.2 Bovine
  • 5.3 Porcine
  • 5.4 Other Sources

6 Global Heparin Market, By Administration Route

  • 6.1 Introduction
  • 6.2 Subcutaneous
  • 6.3 Intravenous
  • 6.4 Other Administration Routes

7 Global Heparin Market, By Dosage Form

  • 7.1 Introduction
  • 7.2 Solution
  • 7.3 Injection
  • 7.4 Other Dosage Forms

8 Global Heparin Market, By Ingredient

  • 8.1 Introduction
  • 8.2 Sodium
  • 8.3 Calcium
  • 8.5 Other Ingredients

9 Global Heparin Market, By Therapeutics

  • 9.1 Introduction
  • 9.2 Respiratory
  • 9.3 Cardiovascular
  • 9.4 Nephrology
  • 9.5 Oncology
  • 9.6 Central Nervous System
  • 9.7 Other Therapeutics

10 Global Heparin Market, By Product

  • 10.1 Introduction
  • 10.2 Unfractionated Heparin
  • 10.3 Low Molecular Weight Heparin
  • 10.4 Ultra-low Molecular Weight Heparin
  • 10.5 Other Products

11 Global Heparin Market, By Application

  • 11.1 Introduction
  • 11.2 Deep Vein Thrombosis
  • 11.3 Coronery Artery Disease
  • 11.4 Pulmonary Embolism
  • 11.5 Atrial Fibrillation
  • 11.6 Venous Thromboembolism
  • 11.7 Renal Impairment
  • 11.8 Heart Attack
  • 11.9 Other Applications

12 Global Heparin Market, By Distribution Channel

  • 12.1 Introduction
  • 12.2 Hospitals
  • 12.3 Drug Stores
  • 12.4 Online Pharmacies
  • 12.5 Retail Pharmacies

13 Global Heparin Market, By End User

  • 13.1 Introduction
  • 13.2 Inpatient
  • 13.3 Outpatient
  • 13.4 Homecare
  • 13.5 Other End Users

14 Global Heparin Market, By Geography

  • 14.1 Introduction
  • 14.2 North America
    • 14.2.1 US
    • 14.2.2 Canada
    • 14.2.3 Mexico
  • 14.3 Europe
    • 14.3.1 Germany
    • 14.3.2 UK
    • 14.3.3 Italy
    • 14.3.4 France
    • 14.3.5 Spain
    • 14.3.6 Rest of Europe
  • 14.4 Asia Pacific
    • 14.4.1 Japan
    • 14.4.2 China
    • 14.4.3 India
    • 14.4.4 Australia
    • 14.4.5 New Zealand
    • 14.4.6 South Korea
    • 14.4.7 Rest of Asia Pacific
  • 14.5 South America
    • 14.5.1 Argentina
    • 14.5.2 Brazil
    • 14.5.3 Chile
    • 14.5.4 Rest of South America
  • 14.6 Middle East & Africa
    • 14.6.1 Saudi Arabia
    • 14.6.2 UAE
    • 14.6.3 Qatar
    • 14.6.4 South Africa
    • 14.6.5 Rest of Middle East & Africa

15 Key Developments

  • 15.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 15.2 Acquisitions & Mergers
  • 15.3 New Product Launch
  • 15.4 Expansions
  • 15.5 Other Key Strategies

16 Company Profiling

  • 16.1 LEO Pharma A/S
  • 16.2 Dr. Reddy's Laboratories Ltd
  • 16.3 Aspen Holdings
  • 16.4 Novartis AG
  • 16.5 GlaxoSmithKline plc
  • 16.6 Teva Pharmaceuticals
  • 16.7 Fresenius SE & Co
  • 16.8 Sanofi
  • 16.9 Viatris Inc
  • 16.10 Baxter International Inc
  • 16.11 Pfizer Inc
  • 16.12 United Biotech Ltd
  • 16.13 Syntex SA
  • 16.14 B. Braun Medical Inc
  • 16.15 Leap Labchem Co
  • 16.16 Bristol-Myers Squibb Co
  • 16.17 Anselm Pharmaceuticals

List of Tables

  • Table 1 Global Heparin Market Outlook, By Region (2020-2028) ($MN)
  • Table 2 Global Heparin Market Outlook, By Source (2020-2028) ($MN)
  • Table 3 Global Heparin Market Outlook, By Bovine (2020-2028) ($MN)
  • Table 4 Global Heparin Market Outlook, By Porcine (2020-2028) ($MN)
  • Table 5 Global Heparin Market Outlook, By Other Sources (2020-2028) ($MN)
  • Table 6 Global Heparin Market Outlook, By Administration Route (2020-2028) ($MN)
  • Table 7 Global Heparin Market Outlook, By Subcutaneous (2020-2028) ($MN)
  • Table 8 Global Heparin Market Outlook, By Intravenous (2020-2028) ($MN)
  • Table 9 Global Heparin Market Outlook, By Other Administration Routes (2020-2028) ($MN)
  • Table 10 Global Heparin Market Outlook, By Dosage Form (2020-2028) ($MN)
  • Table 11 Global Heparin Market Outlook, By Solution (2020-2028) ($MN)
  • Table 12 Global Heparin Market Outlook, By Injection (2020-2028) ($MN)
  • Table 13 Global Heparin Market Outlook, By Other Dosage Forms (2020-2028) ($MN)
  • Table 14 Global Heparin Market Outlook, By Ingredient (2020-2028) ($MN)
  • Table 15 Global Heparin Market Outlook, By Sodium (2020-2028) ($MN)
  • Table 16 Global Heparin Market Outlook, By Calcium (2020-2028) ($MN)
  • Table 17 Global Heparin Market Outlook, By Other Ingredients (2020-2028) ($MN)
  • Table 18 Global Heparin Market Outlook, By Therapeutics (2020-2028) ($MN)
  • Table 19 Global Heparin Market Outlook, By Respiratory (2020-2028) ($MN)
  • Table 20 Global Heparin Market Outlook, By Cardiovascular (2020-2028) ($MN)
  • Table 21 Global Heparin Market Outlook, By Nephrology (2020-2028) ($MN)
  • Table 22 Global Heparin Market Outlook, By Oncology (2020-2028) ($MN)
  • Table 23 Global Heparin Market Outlook, By Central Nervous System (2020-2028) ($MN)
  • Table 24 Global Heparin Market Outlook, By Other Therapeutics (2020-2028) ($MN)
  • Table 25 Global Heparin Market Outlook, By Product (2020-2028) ($MN)
  • Table 26 Global Heparin Market Outlook, By Unfractionated Heparin (2020-2028) ($MN)
  • Table 27 Global Heparin Market Outlook, By Low Molecular Weight Heparin (2020-2028) ($MN)
  • Table 28 Global Heparin Market Outlook, By Ultra-low Molecular Weight Heparin (2020-2028) ($MN)
  • Table 29 Global Heparin Market Outlook, By Other Products (2020-2028) ($MN)
  • Table 30 Global Heparin Market Outlook, By Application (2020-2028) ($MN)
  • Table 31 Global Heparin Market Outlook, By Deep Vein Thrombosis (2020-2028) ($MN)
  • Table 32 Global Heparin Market Outlook, By Coronery Artery Disease (2020-2028) ($MN)
  • Table 33 Global Heparin Market Outlook, By Pulmonary Embolism (2020-2028) ($MN)
  • Table 34 Global Heparin Market Outlook, By Atrial Fibrillation (2020-2028) ($MN)
  • Table 35 Global Heparin Market Outlook, By Venous Thromboembolism (2020-2028) ($MN)
  • Table 36 Global Heparin Market Outlook, By Renal Impairment (2020-2028) ($MN)
  • Table 37 Global Heparin Market Outlook, By Heart Attack (2020-2028) ($MN)
  • Table 38 Global Heparin Market Outlook, By Other Applications (2020-2028) ($MN)
  • Table 39 Global Heparin Market Outlook, By Distribution Channel (2020-2028) ($MN)
  • Table 40 Global Heparin Market Outlook, By Hospitals (2020-2028) ($MN)
  • Table 41 Global Heparin Market Outlook, By Drug Stores (2020-2028) ($MN)
  • Table 42 Global Heparin Market Outlook, By Online Pharmacies (2020-2028) ($MN)
  • Table 43 Global Heparin Market Outlook, By Retail Pharmacies (2020-2028) ($MN)
  • Table 44 Global Heparin Market Outlook, By End User (2020-2028) ($MN)
  • Table 45 Global Heparin Market Outlook, By Inpatient (2020-2028) ($MN)
  • Table 46 Global Heparin Market Outlook, By Outpatient (2020-2028) ($MN)
  • Table 47 Global Heparin Market Outlook, By Homecare (2020-2028) ($MN)
  • Table 48 Global Heparin Market Outlook, By Other End Users (2020-2028) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.